# Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

> **NCT00436930** · PHASE2 · COMPLETED · sponsor: **Hoag Memorial Hospital Presbyterian** · enrollment: 200 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** autologous tumor cell vaccine
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** therapeutic autologous dendritic cells

## Key facts

- **NCT ID:** NCT00436930
- **Lead sponsor:** Hoag Memorial Hospital Presbyterian
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436930, "Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00436930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*